Lack of diagnostic pluripotentiality in patients at clinical high risk for psychosis: Specificity of comorbidity persistence and search for pluripotential subgroups

Schizophrenia Bulletin

Volumn 44, Issue 2, 2018, Pages 254-263

  Woods, Scott ^a   Powers, Albert ^a   Taylor, Jerome ^b,c   Davidson, Charlie ^a,d,e   Johannesen, Jason ^a   Addington, Jean ^f   Perkins, Diana ^g   Bearden, Carrie ^h   Cadenhead, Kristin ⁱ   Cannon, Tyrone ^j,k   Cornblatt, Barbara ^l   Seidman, Larry ^m   Tsuang, Ming ^i,m   Walker, Elaine ^d,e   McGlashan, Thomas ^a  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j YALE UNIVERSITY   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ZUCKER HILLSIDE HOSPITAL   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Prodrome diagnosis outcome depression bipolar anxiety pluripotential clinical high risk

Indexed keywords

ADULT; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYCLOTHYMIA; DEPRESSION; DSM-IV; DYSTHYMIA; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; MENTAL PATIENT; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SEPARATION ANXIETY; SOCIAL PHOBIA; ADOLESCENT; CLINICAL TRIAL; FEMALE; MALE; MULTICENTER STUDY; PRODROMAL SYMPTOM; PROGNOSIS; RISK; SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; ANXIETY DISORDERS; BIPOLAR DISORDER; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MOOD DISORDERS; PRODROMAL SYMPTOMS; PROGNOSIS; PSYCHOTIC DISORDERS; RISK; SYNDROME; YOUNG ADULT;

EID: 85045879408     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbx138     Document Type: Article

References (82)

1. Fusar-Poli P. The Clinical High-Risk State for Psychosis (CHR-P), Version II. Schizophr Bull. 2017;43:44-47.
2. McGlashan TH, Walsh BC, Woods SW. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up. Oxford University Press; 2010.
3. Yung A, Phillips L, McGorry P. Treating Schizophrenia in the Prodromal Phase. Taylor & Francis; 2004.
4. Carol EE, Mittal VA. Resting cortisol level, self-concept, and putative familial environment in adolescents at ultra high-risk for psychotic disorders. Psychoneuroendocrinology. 2015;57:26-36.
5. Walker EF, Brennan PA, Esterberg M, Brasfield J, Pearce B, Compton MT. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J Abnorm Psychol. 2010;119:401-408.
6. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.
7. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703-715.
8. Addington J, Stowkowy J, Cadenhead KS, et al. Early traumatic experiences in those at clinical high risk for psychosis. Early Interv Psychiatry. 2013;7:300-305.
9. Meyer SE, Bearden CE, Lux SR, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol. 2005;15:434-451.
10. Comparelli A, Savoja V, Kotzalidis GD, et al. Factor-structure of the Italian version of the Scale of Prodromal Symptoms (SOPS): a comparison with the English version. Epidemiol Psychiatr Sci. 2011;20:45-54.
11. Lindgren M, Manninen M, Kalska H, et al. Predicting psychosis in a general adolescent psychiatric sample. Schizophr Res. 2014;158:1-6.
12. Loewy RL, Therman S, Manninen M, Huttunen MO, Cannon TD. Prodromal psychosis screening in adolescent psychiatry clinics. Early Interv Psychiatry. 2012;6:69-75.
13. Addington J, Cadenhead KS, Cannon TD, et al.; North American Prodrome Longitudinal Study. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33:665-672.
14. Addington J, Cornblatt BA, Cadenhead KS, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800-805.
15. Kimhy D, Corcoran C, Harkavy-Friedman JM, Ritzler B, Javitt DC, Malaspina D. Visual form perception: a comparison of individuals at high risk for psychosis, recent onset schizophrenia and chronic schizophrenia. Schizophr Res. 2007;97:25-34.
16. Kline E, Thompson E, Demro C, Bussell K, Reeves G, Schiffman J. Longitudinal validation of psychosis risk screening tools. Schizophr Res. 2015;165:116-122.
17. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.
18. Fusar-Poli P, Hobson R, Raduelli M, Balottin U. Reliability and validity of the Comprehensive Assessment of the At Risk Mental State, Italian version (CAARMS-I). Curr Pharm Des. 2012;18:386-391.
19. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107-120.
20. Brent BK, Thermenos HW, Keshavan MS, Seidman LJ. Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings. Child Adolesc Psychiatr Clin N Am. 2013;22:689-714.
21. Dutt A, Tseng HH, Fonville L, et al. Exploring neural dysfunction in 'clinical high risk' for psychosis: a quantitative review of fMRI studies. J Psychiatr Res. 2015;61:122-134.
22. Nagai T, Tada M, Kirihara K, Araki T, Jinde S, Kasai K. Mismatch negativity as a “translatable” brain marker toward early intervention for psychosis: a review. Front Psychiatry. 2013; 4.
23. NHS England. Achieving Better Access to Mental Health Services by 2020. 2014. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/361648/men-tal-health-access.pdf.
24. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Children and Young People: Recognition and Management. 2016. https://www.nice.org.uk/guidance/cg155/
25. Fusar-Poli P, Rocchetti M, Sardella A, et al. Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis. Br J Psychiatry. 2015;207:198-206.
26. Woods SW, Miller TJ, McGlashan TH. The “prodromal” patient: both symptomatic and at-risk. CNS Spectr. 2001;6:223-232.
27. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120:23-37.
28. Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2014;44:17-24.
29. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated psychosis syndrome: ready for DSM-5.1? Annu Rev Clin Psychol. 2014;10:155-192.
30. McGorry P, van Os J. Redeeming diagnosis in psychiatry: timing versus specificity. Lancet. 2013;381:343-345.
31. Nieman DH, McGorry PD. Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. Lancet Psychiatry. 2015;2:825-834.
32. Oxford English Dictionary. 2017.http://www.oed.com/view/Entry/146211?
33. Merriam-Webster. 2017. https://www.merriam-webster.com/dictionary/pluripotent
34. Addington J, Liu L, Perkins DO, Carrion RE, Keefe RS, Woods SW. The role of cognition and social functioning as predictors in the transition to psychosis for youth with attenuated psychotic symptoms. Schizophr Bull. 2017;43:57-63.
35. Addington J, Piskulic D, Liu L, et al. Comorbid diagnoses for youth at clinical high risk of psychosis. Schizophr Res. 2017.
36. Salokangas RK, Ruhrmann S, von Reventlow HG, et al.; EPOS group. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective followup of 245 clinical high-risk outpatients in four countries. Schizophr Res. 2012;138:192-197.
37. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40:120-131.
38. Svirskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res. 2005;75:439-446.
39. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85:124-131.
40. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68:37-48.
41. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35:894-908.
42. Rettew DC, Lynch AD, Achenbach TM, Dumenci L, Ivanova MY. Meta-analyses of agreement between diagnoses made from clinical evaluations and standardized diagnostic interviews. Int J Methods Psychiatr Res. 2009;18:169-184.
43. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
44. Robins LN, Locke BZ, Regier DA. An overview of psychiatric disorders in America. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: Maxwell Mcmillan International; 1991.
45. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
46. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
47. Kessler RC, Avenevoli S, Costello EJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012;69:372-380.
48. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35:383-402.
49. Achim AM, Maziade M, Raymond E, Olivier D, Mérette C, Roy MA. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011;37:811-821.
50. Altamura AC, Serati M, Albano A, Paoli RA, Glick ID, Dell'Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011;261:489-508.
51. Seow LSE, Ong C, Mahesh MV, et al. A systematic review on comorbid post-traumatic stress disorder in schizophrenia. Schizophr Res. 2016;176:441-451.
52. Swets M, Dekker J, van Emmerik-van Oortmerssen K, et al. The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. Schizophr Res. 2014;152:458-468.
53. Sim K, Swapna V, Mythily S, et al. Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience. Acta Psychiatr Scand. 2004;109:23-29.
54. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65:28-37.
55. Webb JR, Addington J, Perkins DO, et al. Specificity of incident diagnostic outcomes in patients at clinical high risk for psychosis. Schizophr Bull. 2015;41:1066-1075.
56. Fusar-Poli P, Rutigliano G, Stahl D, et al. Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. Eur Psychiatry. 2017;42:49-54.
57. Addington J, Cadenhead KS, Cornblatt BA, et al. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res. 2012;142:77-82.
58. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition, (SCID-I/NP Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, 2002.
59. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
60. Walker EF, Cornblatt BA, Addington J, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009;115:50-57.
61. Cadenhead KS, Addington J, Cannon T, et al. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry. 2010;4:220-226.
62. Woods SW, Addington J, Bearden CE, et al. Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. Schizophr Res. 2013;148:99-104.
63. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36:267-275.
64. Kiernan M, Kraemer HC, Winkleby MA, King AC, Taylor CB. Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol Methods. 2001;6:35-48.
65. Lee TY, Lee J, Kim M, Choe E, Kwon JS. Can we predict psychosis outside of the psychosis risk state? A systematic review of risk syndromes for nonpsychotic disorders. Schizophr Bull.
66. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
67. Lam MM, Hung SF, Chen EY. Transition to psychosis: 6-month follow-up of a Chinese high-risk group in Hong Kong. Aust N Z J Psychiatry. 2006;40:414-420.
68. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006;32:166-178.
69. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 2010;116:168-172.
70. Conrad AM, Lewin TJ, Sly KA, et al. Utility of risk-status for predicting psychosis and related outcomes: evaluation of a 10-year cohort of presenters to a specialised early psychosis community mental health service. Psychiatry Res. 2017;247:336-344.
71. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry. 2015;172:249-258.
72. Rutigliano G, Valmaggia L, Landi P, et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. J Affect Disord. 2016;203:101-110.
73. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C. 'A rose is a rose is a rose', but at-risk criteria differ. Psychopathology. 2013;46:75-87.
74. Fusar-Poli P, Cappucciati M, De Micheli A, et al. Diagnostic and prognostic significance of brief limited intermittent psychotic symptoms (BLIPS) in individuals at ultra high risk. Schizophr Bull. 2017;43:48-56.
75. Fusar-Poli P, Schultze-Lutter F, Cappucciati M, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42:732-743.
76. Fusar-Poli P, Rutigliano G, Stahl D, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016;73:1260-1267.
77. Lawrence D, Hafekost J, Johnson SE, et al. Key findings from the second Australian Child and Adolescent Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry. 2016;50:876-886.
78. Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry. 2016;73:211-220.
79. Studerus E, Ramyead A, Riecher-Rössler A. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychol Med. 2017;47:1163-1178.
80. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220-229.
81. Woods SW, Walsh BC, Addington J, et al. Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res. 2014;158:69-75.
82. Modinos G, Allen P, Frascarelli M, et al. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychol Med. 2014;44:3491-3501.